Long-term Obligation - Additional Information (Detail) (USD $)
|
3 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 19 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2014
|
Mar. 31, 2013
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Aug. 31, 2012
Financing Agreement with Biopharma
|
Mar. 31, 2014
Financing Agreement with Biopharma
|
Dec. 31, 2013
Financing Agreement with Biopharma
|
Mar. 31, 2014
Financing Agreement with Biopharma
|
Apr. 30, 2014
Financing Agreement with Biopharma
Subsequent Events
|
Aug. 31, 2012
Financing Agreement with Biopharma
Cash Required Under Debt Covenants
|
Mar. 31, 2014
Maximum
Financing Agreement with Biopharma
|
Aug. 31, 2012
Maximum
Financing Agreement with Biopharma
|
Mar. 31, 2014
Maximum
Financing Agreement with Biopharma
Quarterly Payment During 2014
|
Mar. 31, 2014
Maximum
Financing Agreement with Biopharma
Quarterly Payment During 2015
|
Mar. 31, 2014
Maximum
Financing Agreement with Biopharma
Quarterly Payment During 2016 and Later
|
Aug. 31, 2012
Minimum
Financing Agreement with Biopharma
Cash Required Under Debt Covenants
|
|
Debt Instrument [Line Items] | ||||||||||||||||
Proceeds from issuance of long-term obligation, net of cash paid for issuance costs | $ 30,000,000 | |||||||||||||||
Cumulative payments to be made under financing agreement | 45,000,000 | |||||||||||||||
Aggregate payments to long-term obligations | 995,000 | 2,020,000 | 1,025,000 | 1,000,000 | ||||||||||||
Payment obligation based on a percentage of net product sales | 20.00% | 50.00% | ||||||||||||||
Quarterly payment amount cap | 3,000,000 | 3,750,000 | 0 | |||||||||||||
Percentage of payments received for upfront, milestone or other contingent fees | 20.00% | 20.00% | ||||||||||||||
Increase in percentage used to calculate long term payment obligations, description | The percentage used to calculate our payments to Biopharma would increase to 50 percent and any applicable payment caps would lapse if we (i) fail to provide Biopharma with certain information regarding our promotion and sales of Covered Products, (ii) do not devote a commercially reasonable amount of resources to the promotion and marketing of the Covered Products or (iii) violate the indebtedness covenant by incurring indebtedness greater than the sum of earnings before interest, taxes, depreciation and amortization, including such items as non-cash stock-based compensation, (EBITDA) for the four calendar quarters preceding such incurrence and, in each case, fail to cure within the applicable cure period. | |||||||||||||||
Debt covenant, description | Pursuant to this agreement, we are not allowed to pay a dividend or other cash distribution, unless we will have cash and cash equivalents in excess of $50.0 million after such payment. | |||||||||||||||
Cash and cash equivalents | 43,618,000 | 81,460,000 | 54,877,000 | 93,032,000 | 50,000,000 | |||||||||||
Accretion of interest expense | 1,044,000 | 1,115,000 | 7,100,000 | |||||||||||||
Long term debt carrying value | 35,100,000 | 35,100,000 | 35,100,000 | |||||||||||||
Issuance costs capitalized | 140,000 | 140,000 | ||||||||||||||
Unamortized issuance cost | $ 80,000 | $ 87,000 | $ 80,000 |